Reviva Pharmaceuticals (NASDAQ:RVPH) Rating Increased to Strong-Buy at Roth Capital

Roth Capital upgraded shares of Reviva Pharmaceuticals (NASDAQ:RVPH) to a strong-buy rating in a research note released on Friday,Zacks.com reports.

A number of other equities research analysts have also commented on the company. EF Hutton Acquisition Co. I raised Reviva Pharmaceuticals to a “strong-buy” rating in a research report on Monday, September 23rd. Roth Mkm initiated coverage on shares of Reviva Pharmaceuticals in a research report on Friday. They set a “buy” rating and a $7.00 price target on the stock. Finally, Maxim Group upgraded shares of Reviva Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.00 price objective for the company in a research note on Friday. Four investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, Reviva Pharmaceuticals currently has an average rating of “Buy” and an average target price of $11.25.

Reviva Pharmaceuticals Stock Up 0.5 %

Shares of Reviva Pharmaceuticals stock opened at $1.88 on Friday. The stock has a market cap of $62.87 million, a price-to-earnings ratio of -1.69 and a beta of -0.12. Reviva Pharmaceuticals has a twelve month low of $0.60 and a twelve month high of $4.83. The company’s fifty day moving average is $1.56 and its 200 day moving average is $1.29.

Institutional Investors Weigh In On Reviva Pharmaceuticals

An institutional investor recently raised its position in Reviva Pharmaceuticals stock. Geode Capital Management LLC raised its position in shares of Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) by 17.9% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 278,496 shares of the company’s stock after buying an additional 42,376 shares during the period. Geode Capital Management LLC owned about 0.83% of Reviva Pharmaceuticals worth $401,000 at the end of the most recent reporting period. Institutional investors own 63.18% of the company’s stock.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.